U.S. Bicycle Market Trends - The U.S. bicycle market faces high inventory levels in 2023 due to explosive consumption during 2020-2022, with sales weakened by interest rate hikes and high inflation. Brands are offering 30%-40% discounts to clear inventory, putting pressure on small and medium brands[30] - U.S. e-bike sales surpassed 1 million units in 2023, growing 25% YoY. The North American e-bike market is projected to reach $4.1 billion by 2028[36] European E-bike Market Trends - The European e-bike market is projected to reach 12 million units by 2030, with a shift towards leisure, short-distance commuting, and intelligent transportation. Traditional bicycle demand is declining sharply[31] - European e-bike market inventory remains high, with 30%-40% discounts offered. The UK reduced anti-dumping duties on Chinese e-bikes from 62.1% to 16.2%, with a total tax rate of 33.4%[37] Global E-bike Market Growth - The global e-bike market is expected to grow from $28.9 billion in 2023 to $52.6 billion by 2028, with a 12% CAGR. The e-cargo bike market reached $2.04 billion in 2023[35] Company Market Position and Competitors - The company holds 25% of the global bicycle control parts market and 15% of the suspension fork market, with main competitors being Suntour (70%) and RST (10%)[39] - Competitor SR has expanded production capacity in Germany and Taiwan, with 6 service centers in Germany, strengthening its local presence[41] Shared Mobility Challenges - The U.S. shared e-scooter market faces challenges, with Bird Global filing for bankruptcy in December 2023[42] - European e-scooter shipments declined 50%-70% in 2023, with Xiaomi reducing its annual budget by over 90%, cutting approximately 900,000 units[44] Shipping and Logistics - Red Sea shipping crisis caused container shipping rates to surge by nearly 600%, with rates for a 40-foot container exceeding $10,000[49] - Shanghai to US West Coast shipping rates rose 43.2% to $3,974/FEU, while Shanghai to US East Coast rates increased 47.9% to $5,813/FEU[50] - New FAK rates effective January 15 set 40-foot container rates at $5,000 for US West Coast and $7,000 for East Coast/Gulf ports[51] Shared Mobility Mergers and Market Leaders - Tier Mobility and Dott merger expected to create Europe's largest shared mobility operator with combined revenue exceeding €200 million[52][54] - Ninebot maintains China's top position in smart two-wheeled electric vehicles with leading sales in 4000+/5000+ RMB premium segments[56] - Ninebot's global electric scooter production surpassed 10 million units, with 2.3 million units sold in 2020, accounting for 85% of China's total production[59] Global Electric Scooter Market Forecast - QY Research forecasts global electric scooter production to reach 10.01 million units by 2027, with a market value of $3.34 billion[59] - Boston Consulting Group predicts global smart electric scooter market could reach $50 billion by 2025, with $15 billion in Europe/US and $8 billion in China[59] Micromobility Trends in Australia - Australia's micromobility market grew fivefold since 2017, with over 250,000 personal electric scooters in use[60] - 97% of Australian users find electric scooters more enjoyable than e-bikes, with 85% using them for leisure and 30% planning to increase usage[60] Electric Scooter Market in Russia - Electric scooter sales in Russia increased by 43% year-on-year, reaching 245,000 units in Q1 2023[62] - 85% of personal mobility vehicle purchases in Russia are electric scooters, with 10% being electric bicycles[62] - Shared electric scooter users in Russia aged 50+ increased by 84% over the past year[63] Elderly and Disabled Assistive Devices Market - The global elderly and disabled assistive devices market is projected to reach 299.31 billion yuan by 2030, with a CAGR of 9.11% from 2023[69] - North America holds the largest share of the global wheelchair market at 32.47% in 2023[69] - The Asia-Pacific region is the fastest-growing wheelchair market, expected to grow at a CAGR of 11.8% from 2023 to 2028[73] Rehabilitation Medical Device Market in China - China's rehabilitation medical device market is projected to reach 67 billion yuan by 2023, growing at a CAGR of 19.1%[74] - Global electric wheelchair retail sales are expected to reach 322.023 billion yuan in 2023, a 48.3% increase from 2022[75] - Smart electric wheelchair production is expected to reach 183.021 billion yuan in 2023, a 58.4% increase from 2022[75] - China's electric wheelchair production reached approximately 2.56 million units in 2022[75] Financial Performance and Revenue Decline - Total operating revenue decreased by 47.18% to RMB 963.92 million in 2023 compared to RMB 1.82 billion in 2022[90] - Bicycle parts revenue dropped by 55.47% to RMB 666.58 million, accounting for 69.15% of total revenue[90] - Sports and fitness rehabilitation equipment revenue decreased by 9.02% to RMB 283.47 million, making up 29.41% of total revenue[90] - Domestic sales accounted for 42.06% of total revenue, decreasing by 37.81% to RMB 405.39 million[90] Production and Sales Volume Decline - Bicycle parts sales volume fell by 54.47% to 2.01 million units, with production volume dropping by 58.82% to 1.78 million units[93] - Sports and fitness rehabilitation equipment sales volume decreased by 11.07% to 208,100 units, with production volume down by 5.98% to 195,100 units[93] Customer and Supplier Concentration - Top five customers contributed 35.15% of total sales, with the largest customer accounting for 16.54% of total revenue[99][100] - Top five suppliers accounted for 16.03% of total procurement, with the largest supplier contributing 3.61%[100] Subsidiary Establishment and R&D - The company established a new subsidiary, Shenzhen Laiqi Technology Co., Ltd., in October 2023 with a registered capital of RMB 10 million[98] - R&D expenses decreased by 19.44% to RMB 45.58 million in 2023 compared to RMB 56.58 million in 2022[102][104] - R&D personnel decreased by 13.25% to 406 in 2023 from 468 in 2022, with a slight increase in R&D personnel ratio to 16.76%[103] Cash Flow and Financial Activities - Operating cash flow decreased by 25.59% to RMB 274.81 million in 2023 from RMB 369.32 million in 2022[105] - Investment cash inflow surged by 2311.38% to RMB 58.79 million in 2023 due to the recovery of structured deposits[106] - Investment cash outflow increased by 112.83% to RMB 170.11 million in 2023, mainly due to increased cash expenditures on fixed assets[106] - Net cash flow from financing activities improved by 33.86% to a negative RMB 172.31 million in 2023[106] Profit and Non-Operating Income - Net profit was RMB 18.34 million, significantly lower than the operating cash flow of RMB 276.22 million, mainly due to reduced inventory and lower depreciation expenses[107] - Non-operating income reached RMB 24.15 million, accounting for 172.78% of total profit, primarily from temporary relocation fees[109] - Asset impairment losses amounted to RMB 6.49 million, accounting for 46.42% of total profit, mainly due to inventory obsolescence and idle fixed assets[109] - Government subsidies contributed RMB 1.60 million, accounting for 11.43% of total profit[109] Strategic Goals and Market Expansion - Revenue growth is the primary goal, with a focus on new product development and new customer acquisition[155] - Actively visiting overseas customers to develop new business opportunities[155] - Participating in domestic medical exhibitions to expand the domestic market[155] - Investing in the development of manual and electric wheelchair ODM products[155] - Developing proprietary ODM products, such as electric wheelchairs with lifting mechanisms[155] - Establishing a cost reduction project to meet customer pricing requirements[155] - Optimizing business and operational management processes to prepare for future growth[155] Export Sales and Tariff Impact - Direct export sales accounted for 64.28% of total sales in 2022[156] - Bicycle parts exports are indirectly affected by US tariffs but not by EU anti-dumping duties[156] Corporate Governance and Independence - The company has established a comprehensive internal audit system, with an internal audit institution reporting directly to the Board Audit Committee, ensuring independence and effectiveness in auditing internal controls and financial activities[170] - The company maintains complete independence in assets, personnel, finance, organization, and business operations, with no reliance on shareholders for production or business premises[172] - The company's personnel, including directors, supervisors, and senior management, are independently appointed and remunerated, with no overlap in roles with shareholders or related enterprises[173] - The company has an independent financial department established since 1991, adhering to the "Enterprise Accounting Standards" and maintaining separate bank accounts and tax filings[174] - The company operates independently in its core business of bicycle parts and sports fitness rehabilitation equipment, with no overlap in business activities with shareholders or related enterprises[175] Shareholder Meetings and Resolutions - The 2022 Annual General Meeting had a 51.17% investor participation rate, with key resolutions including the approval of the 2022 financial report and profit distribution plan[176] Executive Compensation - The company strictly adheres to the "Compensation System for Directors, Supervisors, and Senior Management," with actual compensation for 2023 approved by the Remuneration and Assessment Committee and disclosed in the 2023 annual report[199] - Each director/supervisor receives an annual remuneration of 120,000 RMB (after tax deduction), paid monthly, with taxes withheld by the company[199] - The remuneration for directors and supervisors was revised and approved at the 2022 first extraordinary general meeting, effective from May 2022[199]

深圳信隆健康产业发展股份有限公司 独立董事陈大路 2023 年度述职报告 | 姓名 | 召开股东大会会议次数 | 列席股东大会会议次数 | 备注 | | --- | --- | --- | --- | | 陈大路 | 4 | 4 | —— | 2023年，本人认真参加公司董事会及股东大会，积极了解公司的经营和运作 情况。在每次会议召开前，本人都详细阅读会议资料，为参加会议做好充分的准 备。本人本着勤勉尽责和诚信负责的态度，积极参与讨论并发表独立意见。 1 尊敬的各位股东： 作为深圳信隆健康产业发展股份有限公司的独立董事，本人2023年度严格按 照《中华人民共和国公司法》、《中华人民共和国证券法》、《关于在上市公司 建立独立董事制度的指导意见》、《深圳证券交易所中小板上市公司规范运作指 引》等相关法律法规及本公司《公司章程》中关于独立董事的相关规定，恪尽职 守、勤勉尽责。出席公司董事会和股东大会，了解公司经营发展状况、关注公司 的发展、维护公司的合法权益，对重大事项发表了客观、公正的独立意见。现本 人将2023年履职情况汇报如下： 一、述职第一部分：出席董事会及股东大会情况 本年度，公司共召开了8次董事会会议、 ...

证券代码：002105 证券简称：信隆健康 公告编号： 2024-013 公司将在 2023 年年度报告网上说明会上，在信息披露允许的范围内对投资者普遍 关注的问题进行回答。活动交流期间，投资者仍可登陆活动界面进行互动提问。 深圳信隆健康产业发展股份有限公司 关于 2023 年年度报告网上说明会公开征集问题的 提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司(以下简称"公司")已于 2024 年 4 月 24 日发 布了公司《2023 年年度报告》并于同日披露了《关于举办 2023 年年度报告网上业绩说 明会的公告》。公司将于 2024 年 5 月 17 日（星期五）下午 15:00-17:00 在全景网"投 资者关系互动平台"http://irm.p5w.net 举行 2023 年年度报告网上说明会。 为充分尊重投资者，提升交流的针对性，现就公司 2023 年年度报告网上说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 5 月 14 日 17:00 前访问 https://ir ...

证券代码：002105 证券简称：信隆健康 公告编号：2024-004 深圳信隆健康产业发展股份有限公司 关于2024年度继续开展远期外汇交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司（以下简称：公司）拟继续开展远期外汇交易业务， 经公司第七届董事会第七次会议审议通过《关于 2024 年继续开展远期外汇交易的议案》，现 将具体情况公告如下： 一、开展远期外汇交易的目的 公司拟开展的远期外汇交易业务是为满足正常生产经营需要，以及规避和防范汇率风险 为前提，在未来约定时间以约定汇率水平卖出本币买入外币，或者买入本币卖出外币的交易 行为。 本公司约 50%产品出口，且均为自营出口收入，多采用美元等外币进行结算，而采购多 以国内采购为主，日常需支付的人民币金额较多，公司每月的结汇需求较大，因此当汇率出 现较大波动时，汇兑损益对公司的经营业绩会造成较大影响。现计划开展远期结售汇交易， 主要目的仍然是充分利用远期结售汇的套期保值功能，降低汇率波动对公司的影响，使公司 专注于生产经营。 二、预计开展的远期外汇交易业务情况 （一） ...

证券代码：002105 证券简称：信隆健康 公告编号： 2024-002 董事会同意公司自董事会审议通过之日起 12 个月内，以境内外商业银行作为交易对手方， 进行合计不超过 2,500 万美元的远期结售汇业务。并依公司《远期外汇交易业务内部控制制度》 的规定落实实施。 深圳信隆健康产业发展股份有限公司 第七届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事会会议召开情况 深圳信隆健康产业发展股份有限公司（以下简称：公司）第七届董事会第七次会议通知于 2024 年 3 月 8 日以书面及电子邮件的方式发出，会议于 2024 年 3 月 19 日在公司办公楼 A 栋 2 楼会议室以现场结合视频方式召开。会议应出席董事 11 名，实际出席董事 11 名。会议由董事 长廖学金先生主持。本次会议符合《中华人民共和国公司法》等法律、行政法规、部门规章、 规范性文件和公司《公司章程》的规定。公司监事及高级管理人员列席了本次会议。 二、董事会会议审议情况 会议审议并通过了下列决议： （一）审议《关于 2024 年继续开展远期外汇交易的议案》 ...

证券代码：002105 证券简称：信隆健康 公告编号：2024-003 深圳信隆健康产业发展股份有限公司 第七届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 深圳信隆健康产业发展股份有限公司（以下简称：公司）第七届监事会第七次会议通知于 2024 年 3 月 8 日以书面及电子邮件的方式发出，会议于 2024 年 3 月 19 日在公司办公楼 A 栋 2 楼会议室现以场结合视频方式召开。应参加会议监事 3 名，实际参加会议监事 3 名。会议由监 事会主席黄秀卿女士主持。本次会议符合《中华人民共和国公司法》等法律、行政法规、部门 规章、规范性文件和公司《公司章程》的规定。 二、监事会会议审议情况 会议审议并通过了下列决议： （一）审议《关于 2024 年继续开展远期外汇交易的议案》 表决结果： 3 票同意， 0 票弃权， 0 票反对 决议：全体监事经投票表决，审议通过《关于 2024 年继续开展远期外汇交易的议案》。 监事会同意公司自监事会审议通过之日起 12 个月内，以境内外商业银行作为交易对手方， 进行合计 ...

证券代码：002105 证券简称：信隆健康 公告编号：2024-005 深圳信隆健康产业发展股份有限公司 2024 年为天津信隆提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司（以下简称"公司"）于 2024 年 3 月 19 日召开第七 届董事会第七次会议，经参会董事投票表决以 11 票同意，0 票反对，0 票弃权，审议通过了 《关于 2024 年度为天津信隆实业有限公司向银行申请融资额度提供续保的议案》，同意公司 为天津信隆实业有限公司（以下简称"天津信隆"）2024 年度分别向七家银行（台湾土地银 行、建设银行、民生银行、浦发银行、兴业银行、永丰银行、北京银行）申请总计人民币 25,000 万元的融资额度，提供融资额度 100%的公司连带责任保证。本次担保事项无需提交股东大会 审议。 一、担保情况概述 天津信隆实业有限公司（以下简称"天津信隆"）系公司全资子公司，截至 2024 年 2 月 29 日，天津信隆分别向台湾土地银行、建设银行天津静海支行、民生银行天津分行、上海浦 东发展银行天津分行、兴业银行天津 ...

证券代码：002105 证券简称：信隆健康 公告编号： 2023-062 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳信隆健康产业发展股份有限公司 关于完成工商变更登记及备案的公告 董事会 2023 年 11 月 21 日 深圳信隆健康产业发展股份有限公司（以下简称："公司"）于 2023 年 8 月 24 日召开 第七届董事会第五次会议和第七届监事会第五次会议，2023 年 09 月 14 日召开 2023 年第 二次临时股东大会，审议通过了《关于注销回购专用证券账户剩余股份的议案》、《关于变 更公司注册资本、修订<公司章程>并办理工商变更登记的议案》，同意公司根据《公司法》 等相关规定注销回购专用证券账户中剩余股份 34 万股，并同步将《公司章程》相应条款进 行修订。公司已就本次注销事项履行了通知债权人程序。具体详见刊登于公司指定的信息 披露媒体《证券时报》、巨潮资讯网(www.cninfo.com.cn)的《第七届董事会第五次会议决 议公告》（公告编号：2023-046）、《第七届监事会第五次会议决议公告》（公告编号：2023-047）、 《20 ...

康达律师事务所 股东大会法律意见书 广东省深圳市福田区中心四路一号嘉里建设广场 T1-19 层 19/F, Kerry Plaza Tower 1,1-1 Zhongxin 4th Road, Futian District, Shenzhen Guangdong, PRC. 邮编/Zip Code:518048 电话/Tel:0755-88600388 电子邮箱/E-mail： kangda@kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京市康达（深圳）律师事务所 关于深圳信隆健康产业发展股份有限公司 2023年第三次临时股东大会的 法律意见书 康达股会字 2023 第 0641 号 致：深圳信隆健康产业发展股份有限公司（下称"公司"） 北京市康达（深圳）律师事务所（以下简称"本所"）接受公司的委托，指派 本所律师参加公司 2023 年第三次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下 ...

深圳信隆健康产业发展股份有限公司 2023年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示 1.公司董事会于2023年10月28日在《证券时报》以及巨潮资讯网刊登了《关于召开2023 年第三次临时股东大会的通知》； 2.本次股东大会以现场投票和网络投票表决相结合的方式召开； 3.本次股东大会召开期间无增加、否决或变更提案的情况； 4.本次股东大会不涉及变更以往股东大会已通过的决议。 证券代码：002105 证券简称：信隆健康 公告编号：2023-061 （2）会议召开地点：深圳市宝安区松岗街道办碧头第三工业区信隆公司办公楼A栋2楼会议室 本次股东大会的召集、召开程序符合《公司法》、《上市公司股东大会规则》等法律、行 政法规、部门规章、规范性文件及《公司章程》的规定，合法有效。 （3）会议召开方式：现场投票与网络投票表决相结合 （4）会议召集人：公司董事会 （5）会议主持人：董事长廖学金先生 （6）见 证 律 师：北京市康达（深圳）律师事务所黄劲业律师、吴淑菲律师。 2、参加本次股东大会现场会议和网络投票表决的股东及委托代理 ...